Ipratropium Bromide / Albuterol Sulfate
Pronunciation: IP-ra-TROE-pee-um BROE-mide/al-BUE-ter-ol SUL-fate
- Inhalation aerosol ipratropium bromide 18 mcg/albuterol sulfate 103 mcg per actuation
- Inhalation spray ipratropium bromide 20 mcg/albuterol sulfate 120 mcg per actuation
- Inhalation solution ipratropium bromide 0.5 mg/albuterol sulfate 3 mg per 3 mL
Gen-Combo Sterinebs (Canada)
ratio-Ipra Sal UDV (Canada)
Produces bronchodilation by relaxing the bronchial smooth muscle through beta–2 receptor stimulation.Ipratropium
Antagonizes action of acetylcholine on the bronchial smooth muscle in the lungs, causing bronchodilation.
Indications and Usage
Treatment of bronchospasm associated with COPD in patients requiring more than 1 bronchodilator.
Hypersensitivity to any component of the product; hypersensitivity to atropine or any of its derivatives; hypersensitivity to soya lecithin or related food products, such as soybeans or peanuts ( Combivent only).
Dosage and AdministrationCombivent
Inhalation 2 inhalations 4 times daily (max, 12 inhalations per 24 h).Combivent Respimat
1 inhalation 4 times daily (max, 6 inhalations per 24 h).DuoNeb
Inhalation One 3 mL vial 4 times daily via nebulization with up to 2 additional 3 mL doses daily, if needed.
- For oral inhalation only. Avoid spraying into the nose or eyes. Administer DuoNeb only via nebulizer. Not for injection or oral use.
- Refer to manufacturer's prescribing information for priming of Combivent and Combivent Respimat .
Store at 59° to 86°F. Protect from excessive humidity and freezing. Store pressurized canister with nozzle end down, away from heat or open flame. Do not puncture or discard pressurized canister in incinerator. Discard Combivent Respimat no later than 3 months after first use or when the locking mechanism is engaged, whichever comes first.Inhalation solution
Store between 36° and 77°F. Protect vials from light.
Drug InteractionsAnticholinergic agents (eg, atropine)
Possible additive anticholinergic effects. Avoid coadministration.Beta-adrenergic agonists
Risk of adverse CV effects may be increased. Coadminister with caution.Beta-receptor blocking agents (eg, propranolol)
These agents and albuterol may inhibit the effect of each other. Coadminister with caution.Digoxin
Albuterol component may decrease serum digoxin concentrations and therapeutic effects. Monitor digoxin serum concentrations and clinical response. Adjust the digoxin dose as needed.MAOIs (eg, linezolid, phenelzine), tricyclic antidepressants (eg, amitriptyline)
Concomitant use of these agents or use within 2 wk of stopping such agents may potentiate the CV effects of albuterol. Coadminister with extreme caution.Nonpotassium-sparing diuretics (eg, loop diuretics [eg, furosemide], thiazide diuretics [eg, chlorothiazide])
ECG changes and/or hypokalemia, which may result from administration of nonpotassium-sparing diuretics, can be worsened by albuterol. Although the clinical importance of these effects is not known, coadminister with caution. Monitor potassium concentrations.
Angina, arrhythmia, hypertension, hypotension, palpitation, tachycardia (less than 2%); diastolic BP decreased, myocardial ischemia, systolic BP increased (postmarketing).
Headache (6%); asthenia, dizziness, fatigue, insomnia, nervousness, paresthesia, tremor (less than 2%); coordination difficulty, drowsiness, mental disorder, stimulation (postmarketing).
Pruritus, rash (less than 2%); alopecia, angioedema, hyperhidrosis, skin reaction (postmarketing).
Nasopharyngitis, pharyngitis (4%); dysphonia, eye pain (less than 2%); accommodation disorder, acute eye pain, blurred vision, conjunctival hyperemia, corneal edema, dry throat, drying of secretions, halo vision, hoarseness, increased IOP, mucosal ulcers, mydriasis, nasal congestion, ocular irritation, pharyngeal edema, precipitation or worsening of narrow-angle glaucoma, throat irritation (postmarketing).
Diarrhea, nausea (2%); constipation, dry mouth, dyspepsia, taste perversion, vomiting (less than 2%); GI distress, GI motility disorder, mouth edema, stomatitis (postmarketing).
UTI (2%); dysuria (less than 2%); urinary retention (postmarketing).
Hypokalemia (less than 2%).
Arthralgia, muscle spasm, myalgia (less than 2%); back pain, muscular weakness (postmarketing).
Bronchitis (12%); upper respiratory tract infection (11%); cough, lung disease (6%); dyspnea (5%); respiratory disorders (3%); sinusitis (2%); pharyngolaryngeal pain, wheezing (less than 2%); pneumonia, rhinitis (1%); exacerbation of COPD symptoms, paradoxical bronchospasm (postmarketing).
Chest pain, pain (3%); chest discomfort, influenza-like illness (less than 2%); influenza, leg cramps (1%); allergic-type reactions (including anaphylaxis, laryngospasm; angioedema of tongue, lips, and face; skin rash), edema, increased sputum (less than 2%); aching, flushing, heartburn, metabolic acidosis (postmarketing).
Monitor respiratory status. Periodically monitor BP and pulse rate.
Category C .
Safety and efficacy not established.
Immediate hypersensitivity reactions may occur.
Use with caution.
Use with caution.
Special Risk Patients
Use with caution in patients with narrow-angle glaucoma, convulsive disorders, hyperthyroidism, diabetes mellitus, prostatic hypertrophy, or bladder neck obstruction, and in patients who are unusually responsive to sympathomimetic amines.
CNS stimulation may occur; use cautiously in patients with history of seizures or hyperthyroidism.
Toxic symptoms may occur in patients with CV disorders. Use with caution in patients with coronary insufficiency, arrhythmias, or hypertension.
Dosage adjustment of insulin may be required.
Death may occur with excessive use of inhaled sympathomimetic drugs in patients with asthma.
Transient decreases in potassium levels may occur.
Life-threatening bronchospasms can occur, usually with the first use of a new container.
Angina, arrhythmia, cardiac arrest, dizziness, dry mouth, fatigue, headache, hypertension or hypotension, hypokalemia, insomnia, malaise, nausea, nervousness, palpitations, seizures, tachycardia, tremor.
- Advise patients to continue taking other medications for the same condition as prescribed by their health care provider.
- Advise patients using the nebulizer to read the patients' instructions for use before starting therapy and again with each refill.
- Ensure that patients using inhalation solution can prepare, use, and clean the nebulizer without difficulty.
- Review proper administration technique for patients using inhalation aerosol/spray. Have patients demonstrate technique to ensure effective use of the metered-dose inhaler.
- Instruct patients not to exceed prescribed dose. Advise patients to inform their health care provider if symptoms do not improve or if they worsen, if treatments are needed more often than usual, or if the medication appears to become less effective.
- Instruct patients not to stop the medication once symptoms have been controlled. Continued daily use is necessary to control symptoms.
- Advise patients to carry medical identification (eg, card, bracelet) indicating COPD.
- Caution patients about engaging in activities requiring balance and visual acuity (eg, driving a car, operating appliances or machinery) because dizziness, accommodation disorder, mydriasis, and blurred vision can occur.
- Inform patients to notify their health care provider if they experience changes in vision, difficulty with urination, palpitations, chest pain, rapid heart rate, tremor, or nervousness.
- Inform patients that paradoxical bronchospasm can occur and to discontinue use if this reaction occurs.
Copyright © 2009 Wolters Kluwer Health.